TA
Tamarack Advisers Portfolio holdings
AUM
$2.12M
This Quarter Return
-1.69%
1 Year Return
-56.28%
3 Year Return
-45.76%
5 Year Return
+44.93%
10 Year Return
–
AUM
$169M
AUM Growth
+$169M
(-1.6%)
Cap. Flow
-$296K
Cap. Flow
% of AUM
-0.17%
Top 10 Holdings %
Top 10 Hldgs %
52.9%
Holding
52
New
9
Increased
18
Reduced
9
Closed
6
Top Buys
| 1 |
STRM
Streamline Health Solutions
STRM
|
$5.87M |
| 2 |
CVS Health
CVS
|
$4.77M |
| 3 |
Alkermes
ALKS
|
$4.47M |
| 4 |
BioMarin Pharmaceuticals
BMRN
|
$3.48M |
| 5 |
Collegium Pharmaceutical
COLL
|
$3.2M |
Top Sells
| 1 |
Cigna
CI
|
$11.9M |
| 2 |
United Therapeutics
UTHR
|
$7.07M |
| 3 |
Labcorp
LH
|
$5.86M |
| 4 |
Amgen
AMGN
|
$5.84M |
| 5 |
Merck
MRK
|
$4.31M |
Sector Composition
| 1 | Healthcare | 96.62% |
| 2 | Consumer Staples | 2.07% |
| 3 | Technology | 1.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Lantheus
LNTH
$3.73B
| $14.6M | 8.59% | 208,000 -42,000 | -17% | -$2.95M |
|
|
MDRX
2
DELISTED
Veradigm Inc. Common Stock
MDRX
| $10.4M | 6.13% | 685,000 +135,000 | +25% | +$2.06M |
|
3
Pacira BioSciences
PCRX
$1.2B
| $10.4M | 6.09% | 195,000 +20,000 | +11% | +$1.06M |
|
4
Perrigo
PRGO
$3.27B
| $9.09M | 5.34% | 255,000 +55,000 | +28% | +$1.96M |
|
5
Tenet Healthcare
THC
$16.3B
| $9.03M | 5.3% | 175,000 +15,000 | +9% | +$774K |
|
6
Cerus
CERS
$251M
| $8.73M | 5.13% | 2,425,000 +425,000 | +21% | +$1.53M |
|
7
SI-BONE Inc
SIBN
$719M
| $8.03M | 4.72% | 460,000 -75,000 | -14% | -$1.31M |
|
8
AngioDynamics
ANGO
$417M
| $6.65M | 3.9% | 325,000 +5,000 | +2% | +$102K |
|
9
Phreesia
PHR
$1.88B
| $6.63M | 3.89% | 260,000 +15,000 | +6% | +$382K |
|
|
10
BioMarin Pharmaceuticals
BMRN
$11.2B
| $6.02M | 3.53% | 71,000 +41,000 | +137% | +$3.48M |
|
11
Sanofi
SNY
$121B
| $5.89M | 3.46% | 155,000 +60,000 | +63% | +$2.28M |
|
|
STRM
12
DELISTED
Streamline Health Solutions
STRM
| $5.87M | 3.45% | +4,930,882 | New | +$5.87M |
|
|
13
Cigna
CI
$80.3B
| $5.55M | 3.26% | 20,000 -43,000 | -68% | -$11.9M |
|
14
Viatris
VTRS
$12.3B
| $5.54M | 3.25% | 650,000 +300,000 | +86% | +$2.56M |
|
15
Bioventus
BVS
$495M
| $5.25M | 3.08% | 750,001 | – | – |
|
|
16
Collegium Pharmaceutical
COLL
$1.22B
| $4.81M | 2.82% | 300,000 +200,000 | +200% | +$3.2M |
|
|
17
CVS Health
CVS
$92.8B
| $4.77M | 2.8% | +50,000 | New | +$4.77M |
|
|
18
Alkermes
ALKS
$4.78B
| $4.47M | 2.62% | +200,000 | New | +$4.47M |
|
19
Jazz Pharmaceuticals
JAZZ
$7.75B
| $4M | 2.35% | 30,000 +5,000 | +20% | +$667K |
|
20
DocGo
DCGO
$153M
| $3.72M | 2.18% | 375,000 +200,000 | +114% | +$1.98M |
|
21
Turning Point Brands
TPB
$1.79B
| $3.5M | 2.06% | 165,000 -25,000 | -13% | -$531K |
|
22
AtriCure
ATRC
$1.84B
| $2.64M | 1.55% | 67,500 -32,500 | -33% | -$1.27M |
|
23
Rigel Pharmaceuticals
RIGL
$697M
| $2.36M | 1.39% | 2,000,000 | – | – |
|
24
ICU Medical
ICUI
$3.15B
| $2.26M | 1.33% | 15,000 +2,000 | +15% | +$301K |
|
|
25
Merck
MRK
$210B
| $2.15M | 1.26% | 25,000 -50,000 | -67% | -$4.31M |
|